The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 YM BioSciences Inc  (YMI) Trade Now »     Rate YMI  -  Discuss YMI  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
63.5%
Top:
100.0%
Rate YMI:



YMI Analysis & Videos »


YMI: Bull or Bear?

Stock Research Reports for $UNIS, $ZIOP, $CLSN, $NBY, $CYTR, $ECTE.OB, $IMUC.OB, $YMI Graphic_rating_buy YMI
Mikerun
73%
 -70.59%
in 1173 days
Below are links to third-party stock research reports which are available as PDFs at mikehavRx.com.

<font> Unilife Corp. (NASDAQ:UNIS) </font> <font> - Published 3/31/10 by Griffin Securities, Buy Rating, $15 Price Target </font>

<font> Ziopharm Oncology (NASDAQ:ZIOP) </font> <font> </font> <font> - Published 3/3/10 by Griffin Securities, Buy Rating, $8 Price Target </font>

<font> Celsion Corp. (NASDAQ:CLSN) </font> <font> </font> <font> - Published 3/2/10 by Griffin Securities, Buy Rating, $10 Price Target </font>

<> <> <> <font> NovaBa...
By  Mike Havrilla   (+1.04%  risk: moderate)  04/02/10 53 comments


YM BioSciences (AMEX: YMI): Griffin Reiterates Buy Rating, Ups Price Target to $5.50 Graphic_rating_buy YMI
Mikerun
73%
 +11.21%
in 156 days
(closed on 04/02/10)
On 10/28/09, Griffin Securities issued a research report, reiterating its buy rating on YM BioSciences (AMEX: YMI) (TSX: YM.TO) and increasing the 12-month price target to $5.50 per share. Below is a summary of the rationale behind the updated buy rating and new price target.
 
1.) YMI has 11 global Phase II / III trials ongoing for nimotuzumab (nimo), which is an EGFR-targeting monoclonal antibody with best-in-class potential in an established class of billion dollar drugs with only two other antibodies available that target EGFR, including Erbitux and Vectibix
 
<> 2.)...
By  Mike Havrilla   (+1.04%  risk: moderate)  10/28/09 8 comments


BioMed News Bytes: Arena (NASDAQ: ARNA), ImmunoCellular (OTC: IMUC.OB), YM Bio (AMEX: YMI) Graphic_rating_buy YMI
Mikerun
73%
 -39.55%
in 41 days
(closed on 10/28/09)
Shares of Arena Pharma (NASDAQ: ARNA) (AH $6.58, +34% at 5:10pm ET on heavy, above-average volume for the day) are surging on news that the Company will <font> conduct a conference call Friday 18-September at 8am ET </font> to discuss the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 study (its second pivotal Phase 3 study for this compound) results for its experimental weight loss drug lorcaserin and expects to submit a NDA for FDA approval by year-end based on guidance provided in late March, which is outlined below.
 
<> ...
By  Mike Havrilla   (+1.04%  risk: moderate)  09/17/09 4 comments


Get free stock alert for YMI:
Your Email Address:


YM BioSciences Announces Phase 2 Metastatic Colorectal Cancer Results for Nimotuzumab Graphic_rating_buy YMI
Mikerun
73%
 -41.56%
in 52 days
(closed on 09/26/08)
The table below compares nimotuzumab [nimo] + irinotecan (N-Mab + Iri) data against results obtained from an integrated analysis of four trials of patients treated with Erbitux (cetuximab) + irinotecan (C-Mab + Iri) following irinotecan failure in a similar patient population:


YM BioSciences (YMI) announced preliminary results from a Phase 2 study of nimo in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of the 61 enrolled in the trial. The prospective primary endpoint in the trial is objective tumour r...
By  Mike Havrilla   (+1.04%  risk: moderate)  08/05/08 3 comments


An Update on YM BioSciences from Collins Stewart Conference Presentation Graphic_rating_buy YMI
Mikerun
73%
 +1.32%
in 21 days
(closed on 08/05/08)
YM BioSciences (AMEX: YMI) 1-Year Chart

The Chairman and CEO of Canadian biotech YM BioSciences (YMI), David Allan, presented yesterday at the Collins Stewart Fourth Annual Growth Conference, which provided investors with an overview and update on the prospects for the Company. YM Bio has two late-stage products in development, including the cancer drug nimotuzumab (nimo) and inhaled pain treatment AeroLEF. The stock closed today near all-time lows at 77 cents within a 52-week range of $0.70 - $1.89, resulting in a market cap of just $43 million (M) despite having no ...
By  Mike Havrilla   (+1.04%  risk: moderate)  07/15/08 8 comments





People Bullish on YMI

ishkly
Analyst
N/A
over 3 years ago

Mikerun
Mike Havrilla
Principal
73%
over 3 years ago

Foto
Marian Filo
Principal
62%
over 3 years ago

sh0efalue
Analyst
N/A
over 3 years ago

pennystocks
Analyst
N/A
over 3 years ago


People Bearish on YMI

Tom
Analyst
N/A
over 3 years ago

Pavan S
Analyst
63%
over 5 years ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +32.13% 538
2 Gerald Greene 18.14 +6.82% 289
3 stockmarketfunding.com 17.66 +22.47% 85
4 akiralegrand 13.47 +13.86% 71
5 anup2104 12.13 +175.56% 106


POPULAR STOCKS
Symbol Company Name Sentiment
SBUX Starbucks Corp
GS Goldman Sachs Group Inc The
DELL Dell Inc
NOK Nokia Corp
IBM International Business Machines Corp
JPM JPMorgan Chase & Co

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on YMI


Discussion Wall + Add  
Tom   (+373.02%  risk: conservative)
YMI=undervalued? - YMI- currently the company has about $43 million in cash and $0 debt. The last pr: YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT ...
+   21 replies


More Resources

Graphic_arrow1 About YM BioSciences Inc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch